Literature DB >> 3011223

[Molecular models of the interaction between T4 antigen and HLA class II antigens or the LAV virus].

C Auffray.   

Abstract

HLA class II beta chains contain in their aminoterminal polymorphic domain a highly conserved tetrapeptide (RFDS) also present in protein F encoded by the LAV virus. Homology between this tetrapeptide and the fibronectin cell-attachment site (RGDS) has suggested a role in cell adhesion processes. I propose here that such a structure, that I call adhesiotope, would allow stabilization of intermolecular contacts between molecules present at the surface of interacting cells or viruses. Analysis of a three dimensional model of the T4 antigen suggests that the tetrapeptide RADS is located at the surface of the aminoterminal, immunoglobulin-like domain. A model is proposed in which interaction between the adhesiotopes present in class II antigens (RFDS) and T4 (RADS) is the molecular basis of conjugate formation between antigen presenting cells and T helper lymphocytes. The LAV virus, having the RFDS adhesiotope on its surface, would mimic class II antigens in their interaction with T4 and infect selectively T4 positive cells, resulting in the acquired immune deficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011223

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  2 in total

1.  Mutations in the D strand of the human CD4 V1 domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly.

Authors:  D Piatier-Tonneau; L N Gastinel; G Moussy; B Bénichou; F Amblard; P Vaigot; C Auffray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

2.  Isolation of chicken major histocompatibility complex class II (B-L) beta chain sequences: comparison with mammalian beta chains and expression in lymphoid organs.

Authors:  Y Bourlet; G Béhar; F Guillemot; N Fréchin; A Billault; A M Chaussé; R Zoorob; C Auffray
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.